Therapeutic APAC Molecule Comprising Heparin Conjugated to a Plasma Protein

A method for the manufacture of a medicament comprising an anti-thrombotic molecule having enhanced anti-platelet activity, comprising:

• i) modifying an unfractionated heparin (Hep) chain to produce a reactant product having a N-hydroxysuccinimide ester (—NHS) group;
• ii) conjugating the reactant product of i) with a human plasma protein containing primary amines using a homo-bi-functional cross-linker, the human plasma protein being selected from the group consisting of:
• an albumin, a globulin, a fibrinogen, serum albumin and alpha2-macroglobulin;
• and
• iii) repeating one or both of steps ii) and i) until the number of said heparin chains conjugated to said human plasma protein equals an integer selected from the group of integers consisting of:
• 8, 9, 10, 11, 12, 13, 14, 15, and 16.